What are the open and close dates of the Corona Remedies IPO ?

Corona Remedies IPO will be open between 2025-12-08 and 2025-12-10.

What is the allotment date for the Corona Remedies IPO ?

Corona Remedies IPO allotment date is 2025-12-12. For Corona Remedies IPO allotment status check, you can visit the website of the registrar of the IPO.

Who is the registrar of Corona Remedies IPO ?

For Corona Remedies IPO, the IPO registrar is Bigshare Services Private Limited. You can check Corona Remedies IPO allotment status on the website of the registrar.

Where is the Corona Remedies IPO getting listed?

The shares are proposed to be listed on the BSE and NSE.

When will Corona Remedies IPO shares be credited to your demat account?

The Corona Remedies IPO shares will typically be credited to your demat account one working day before the IPO's listing date, provided your application is successfully allotted.

What is the lot size and minimum order quantity of the Corona Remedies IPO ?

The Corona Remedies IPO lot size is 14 and minimum order quantity is 14.

What is the price band for the Corona Remedies IPO ?

Corona Remedies IPO has set the price band for its IPO at 1062 per equity share with a face value of 10.

Corona Remedies IPO

Hospital & Healthcare Services

open

₹14,112Min. investment

Pre-apply
4 Dec
Bid start
8 Dec
Bid end
10 Dec
Allotment
11 Dec
Release of funds
12 Dec
Demat transfer
12 Dec
Listing
15 Dec

Corona Remedies Limited IPO Details

Issue size

₹655Cr

IPO type

Mainboard

Market Cap

₹6,495CrLower than sector avg

Price range

₹1,008 – ₹1,062

Listing ExchangeBSE, NSE

RevenueApr 2024 - Mar 2025

₹1,196CrHigher than sector avg

Lot size

14 shares

Red Herring Prospectus

Read

Growth rate3Y CAGR

16.33%

SectorHospital & Healthcare Services

Price range₹1,008 – ₹1,062

IPO type

Regular

Lot size14 shares

Issue size₹655Cr

Red Herring Prospectus

Read

Market Cap

₹6,495CrLower than sector avg

RevenueApr 2024 - Mar 2025

₹1,196CrHigher than sector avg

Growth rate3Y CAGR

16.33%

Corona Remedies Limited IPO Overview

Corona Remedies Limited IPO date

Corona Remedies Limited IPO will open for subscription on December 08, 2025, and the closing date for the IPO is December 10, 2025. After this, investors are expected to be updated about the allotment status on December 11, 2025. Investors who have been allotted shares can expect them to be credited to their demat account on December 12, 2025. The shares will be listed on the NSE and the BSE on Monday, December 15, 2025.

Corona Remedies Limited IPO price band

The IPO includes an offer for sale. The IPO price band has been set between ₹1,008 to ₹1,062 per share. Interested investors can choose a price within this band to apply for the IPO. The IPO is a book-building issue, comprising an offer for sale of ₹655.37 crore. Corona Remedies Limited IPO listing price will be determined on December 15, 2025. The listing price is the price at which a company’s shares debut on the stock exchanges.

Corona Remedies Limited IPO lot size

Corona Remedies Limited IPO details have been declared. The minimum lot size for an application is 14 shares, and the investor would have to apply for a minimum of 1 lot. Meanwhile, the IPO issue size is approximately ₹655.37 crore.

Checklist

Quality analysis

Revenue growth

Company valuation

Earnings expansion

Risk analysis

Debt to Equity ratio

Promoter holdings

Shares pledged

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Compare

Companies in this sector

Max Healthcare Institute Ltd

Apollo Hospitals Enterprise Ltd

Fortis Healthcare Ltd

Revenue

Higher revenue means strong sales and good market demand

This IPO

₹1,196Cr

This sector

₹810.55Cr

Compare with companies

PAT

Higher PAT means strong profitability and efficient cost management

This IPO

₹149.4Cr

This sector

₹87.66Cr

Compare with companies

Market cap

Higher market cap means strong confidence but may suggest overvaluation

This IPO

₹6,495Cr

This sector

₹10,075.9Cr

Compare with companies

P/E ratio

Lower ratio usually means stock is undervalued

This IPO

43.47

This sector

55.14

Compare with companies

D/E ratio

Lower ratio usually means fewer liabilities

This IPO

0.10

This sector

0.40

Compare with companies

Objectives

Carry out the offer for sale

The IPO is a complete offer-for-sale (OFS). Net IPO proceeds will go to selling shareholders.

Listing on stock exchanges

The company want to achieve the benefits of listing its shares on the stock exchanges.

Strength and Weakness

Strong portfolio in fast-growing therapeutic areas

The firm has a deep anchor in the fast-growing categories in India: women's healthcare, cardio-diabeto, pain management, and urology. These four areas together contributed 68.26% of domestic sales, growing at a 22.40% CAGR from MAT June 2022-2025. This strategic alignment to long-term demand provides volume stability and visibility for the portfolio.

Leadership across flagship “engine brands”

The firm has 27 “engine brands” that alone contributed 72.34% of domestic sales in MAT June 2025. Key brands like COR, Trazer, Cor-9, B-29, Myoril and Tricium dominate their respective sub-categories, with 12 of these brands ranked within the top 5 in their therapeutic segments.

Limited exposure to NLEM list

The company’s portfolio has limited exposure to the National List of Essential Medicines. Only 9.76% of its sales fall under NLEM, which is the 7th lowest amongst the top 30 pharmaceutical companies in IPM, versus 17.51% for the overall pharma market, giving it far better room to protect margins and avoid regulatory price compression.

Growing focus on chronic & sub-chronic therapies

The company has been shifting focus towards categories with longer prescription duration, better patient stickiness, and more profitability. 70.10% of its domestic sales came from chronic/sub-chronic products in MAT June 2025, versus 63.82% in June 2022. This helps ensure recurring revenue and predictable cash flows.

Strong sales infrastructure and deep engagement

The company has built a pan-India commercial engine reaching specialists and super-specialists. ~75.75% of its prescriptions come from specialists vs 60.96% for the broader market, and more than 75% of sales come from urban/semi-urban markets, where purchasing power and compliance are higher.

Geographical concentration

96.33% of revenues are generated domestically in FY25. Approximately 47.30% of domestic sales in MAT June 2025 come from only five western states: Gujarat, Maharashtra, Goa, Chhattisgarh, and MP. Thus, any slowdown in those markets, changes in regulations, or even issues with distributors disproportionately hurt growth.

Raw material and API supply uncertainty

The company does not have long-term contracts with most of its suppliers and has high dependence on third parties for APIs as well as finished goods. Total purchases represented 27.96% of expenses in FY25. Prices are volatile, with suppliers potentially giving higher priority to competitors. There’s also additional dependence on the related-party API supplier, La Chandra Pharmalab.

Trademark protection gaps

Although there are 194 registered trademarks, 67 were opposed / objected / refused / abandoned, and another 29 applications are pending. Some of the engine brands, like Cortel, Argihope, and Dosin, do not have final registrations. In case of similar brand name usage by competitors or any disputes arising, the company could lose brand recognition and revenue.

Heavy dependence on a few therapeutic categories

The company’s product portfolio is concentrated in a limited number of therapeutic categories, such as women's healthcare, cardio-diabeto and pain management therapies. In FY25, these 3 together accounted for 62.40% of total revenue. Any shift in physician prescriptions toward competing alternatives or the launch of viable new alternatives may bring down sales and margins for the company.

Regulatory approvals still pending for the Solan facility

This plant at Solan is one of the major production hubs for the company, but a lot of significant operational approvals are still pending. These include approval for NOC for the extraction of groundwater, authorisation of bio-medical waste, and fire safety NOC. Failure or delay in any of these could lead to forced shutdowns, penalties, or disruptions in production for the company.

About Corona Remedies Limited

Corona Remedies Limited is an India-focused pharmaceutical formulation company that develops, manufactures and markets a wide range of medicines related to women healthcare, heart and diabetes care, pain relief, urology, and more.

According to the CRISIL Intelligence report, Corona Remedies is the 2nd fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM), with domestic sales rising 16.77% much higher than the industry average of 9.21% for Moving Annual Total (MAT) sales between June 2022 and June 2025.

The company offers a diverse portfolio of 71 brands. Out of these, 27 brands account for over 72% of the company’s domestic sales as of June 30 2025, MAT sales. Some of its best-known brands include B-29 (which brings in over ₹100 crore in revenue), Myoril, Tricium, Cortel, Obimet, and Rosuless. Several brands of the company, like Myoril, COR, and Trazer, hold a leadership position and are among the top brands in their respective sub-groups.

The company has two manufacturing facilities in Gujarat and Himachal Pradesh with a total installed capacity of 128.54 crore units per annum across 11 production lines as of June 30, 2025. The Gujarat facility is EU GMP and WHO GMP-certified, while the Himachal Pradesh facility is WHO GMP-approved. A new hormone manufacturing facility in Gujarat is expected to start operations in Q1FY27. The company also invested in La Chandra Pharmalab Private Limited, which operates an EU GMP and WHO GMP-certified hormone API manufacturing facility.

The company operates in several fast-growing therapeutic areas. A big part of its sales comes from women's healthcare, where the company has a strong position with ₹408.03 crore in sales or 28.56% contribution to MAT June 2025 domestic sales. Next, it has a meaningful presence in cardio-diabetes medicines, which generated ₹333.99 crore (23.38% of sales). Pain management contributed ₹168.44 crore or 11.79% of MAT June 2025 sales. In urology, the brand is not so big but competitive with ₹64.67 crore or 4.53% contribution. The remaining therapies and product categories together contribute ₹453.36 crore or 31.74%, creating a wide and diversified base.

The company has a marketing and distribution network of 2,671 medical representatives in 22 states as of June 30, 2025. The distribution network is backed by 22 carrying and forwarding setups and more than 2,000 distributors across India. It targets the "middle of the pyramid" market segment, with specialists and super-specialists contributing 75.75% of prescriptions during MAT June 2025 sales, compared to 60.96% for the overall IPM.

The Indian domestic formulation market, valued at approximately ₹2.30 lakh crore in FY25, represents about 2% of the global pharmaceutical market. The market composition has changed; chronic therapies now represent about 55% and acute therapies 45% of the total domestic formulation market as of FY25. The growth in the chronic segment is expected to outpace the overall market at 8.5-9.5% CAGR between FY25 and FY30. Growth in the acute segment is likely to be slower at 7.5-8.5% CAGR during the same period.

Women's healthcare presents significant growth opportunities in India. The female population of the country has steadily risen to nearly 49% of the total population, accompanied by improved life expectancy and access to healthcare.

The company targets high-growth chronic and sub-chronic therapies that grew at a CAGR of 20.48% between MAT June 2022 and MAT June 2025, much higher than the IPM CAGR of 10.08%. It also has low exposure to the National List of Essential Medications, with 9.76% of total sales under NLEM 2022 compared to 17.51% for the overall IPM, thus assuring greater pricing flexibility.

Now, Corona Remedies Ltd is launching its initial public offering (IPO), which consists of an offer for sale of ₹655.37 crore. Its shares will be listed on the NSE and BSE.

How to pre-apply for the Corona Remedies IPO?

You can pre-apply for the Corona Remedies IPO on Upstox. The pre-application for this IPO, which means the pre-apply open date, usually begins a day before the IPO opens for subscription.

Follow these steps to pre-apply for the IPO:

Login to your Upstox account, using your six-digit PIN
After successfully logging in, click on ‘Discover’
On the Discover tab, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, look for the ‘Corona Remedies IPO’ tab and click on it
Now fill in all the required information, like ‘bid price’ and ‘lot size’
Confirm and click on ‘Pre-Apply’
Accept the mandate on your UPI app

How to apply for the Corona Remedies IPO?

If you are interested in this investment opportunity but unsure how to apply for the Corona Remedies IPO, here are the steps that you need to follow.

When the public issue opens for subscription, one can follow this step-by-step guide on how to apply for the Corona Remedies IPO on Upstox:

Log in to your Upstox account, using your six-digit PIN
After logging in, click on ‘Discover’
On the ‘Discover’ tab, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, look for the ‘Corona Remedies IPO’ tab and click on it
Now fill in all the required information, like ‘bid price’ and ‘lot size’
Confirm and click on ‘Apply’
Accept the mandate on your UPI app

How to check Corona Remedies IPO Allotment Status?

When the allotment process is completed, you can check the status of your application on the Upstox app. Share allotment is generally completed on the next working day after an IPO closes.

Here’s a step-by-step guide on how to check the Corona Remedies IPO allotment status:

Login to your Upstox account, using your six-digit PIN
After logging in, click on ‘Discover’
On the ‘Discover’ page, you will find the ‘Invest in IPO’ section
Under the Invest in IPO section, you will find the ‘View all’ option
Once you click on ‘View all’, you will be directed to the ‘IPO’ tab
In the ‘IPO’ tab, click on ‘My applications’
In ‘My applications’, under the History section, your Corona Remedies IPO allotment status will be mentioned

Latest News on Corona Remedies IPO

Homegrown private equity firm ChrysCapital-backed pharma company Corona Remedies has picked three investment banks to start work on a proposed IPO, which will see the company raise as much as Rs 1,500 crore-2,000 crore, people aware of the matter told Moneycontrol. ChrysCapital acquired a 27.5 percent stake in the company in 2021 for an investment of Rs 670 crore.

Corona Remedies IPO: The initial share sale is solely an offer for sale (OFS) of equity shares aggregating to ₹655.37 crore. There is no fresh issue component.

2 min read

AB InBev's stock surged after strong Q4 results, driven by premium products like Corona. Revenue rose 3.4%, beating expectations. Stock up 9% in Brussels, 17% this year. Corona saw double-digit growth in 30+ markets, with Corona Cero up triple-digits. Despite volume declines, EBITDA rose 8.2%, supported by strong margins and non-alcoholic beer success.

Upcoming IPOs: Listings that are scheduled for next week include Meesho, Aequs, Vidya Wires, Astron Multigrain, Invicta Diagnostic, Speb Adhesives, Ravelcare, Clear Secured, Helloji Holidays, Neochem Bio, Shri Kanha Stainless, Luxury Time, Western Overseas Study Abroad, Flywings Simulator Training and ScaleSauce.

4 min read

Frequently asked questions

How to invest in the Corona Remedies IPO ?

Investors can apply for the Corona Remedies IPO through their Demat account via the stock exchange or through their broker.

What is the issue size of Corona Remedies IPO ?

The issue size of the Corona Remedies IPO is 655 Cr.

What is 'pre-apply' for Corona Remedies IPO ?

Pre-applying for an IPO allows you to submit your application before the official subscription period begins.

Which exchanges will Corona Remedies IPO shares list on?

The IPO shares will typically list on major stock exchanges such as the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), as specified in the IPO prospectus.

Home
/
IPO
/
Corona Remedies IPO

Ipo opens on 8 Dec 2025, 10:00 AM